Summary of MM cases in published studies ofNRAS and KRAS2 mutations
| Study . | KRAS2mutations . | NRAS mutations . | ||
|---|---|---|---|---|
| Medullary disease, at diagnosis [at relapse] (%) . | Extramedullary disease . | Medullary disease, at diagnosis [at relapse] (%) . | Extramedullary disease . | |
| Neri et al4(1989) | 2/43 [2/13] (7) | NA | 11/43 [4/13] (26) | NA |
| Paquette et al5 (1990) | 0/17 (0) | NA | 2/17 (11) | NA |
| Matozaki et al6 (1991) | 0/15 (0) | NA | 4/15 (26) | NA |
| Tanaka et al7 (1992) | 0/10 (0) | NA | 5/10 (50) | NA |
| Portier et al8 (1992) | 2/13 (15)* | 6/15 (40)* | 2/13 (15)* | 6/15 (40)* |
| Corradini et al9 (1993) | 0/77 (0) | 1/13 (7) | 7/77 (9)* | 3/13 (29)* |
| Millar et al10 (1995) | 0/18 (0) | NA | 0/18 (0) | NA |
| Liu et al3 (1996) | 23/139 (16.5) | NA | 29/129 (23) | NA |
| Study . | KRAS2mutations . | NRAS mutations . | ||
|---|---|---|---|---|
| Medullary disease, at diagnosis [at relapse] (%) . | Extramedullary disease . | Medullary disease, at diagnosis [at relapse] (%) . | Extramedullary disease . | |
| Neri et al4(1989) | 2/43 [2/13] (7) | NA | 11/43 [4/13] (26) | NA |
| Paquette et al5 (1990) | 0/17 (0) | NA | 2/17 (11) | NA |
| Matozaki et al6 (1991) | 0/15 (0) | NA | 4/15 (26) | NA |
| Tanaka et al7 (1992) | 0/10 (0) | NA | 5/10 (50) | NA |
| Portier et al8 (1992) | 2/13 (15)* | 6/15 (40)* | 2/13 (15)* | 6/15 (40)* |
| Corradini et al9 (1993) | 0/77 (0) | 1/13 (7) | 7/77 (9)* | 3/13 (29)* |
| Millar et al10 (1995) | 0/18 (0) | NA | 0/18 (0) | NA |
| Liu et al3 (1996) | 23/139 (16.5) | NA | 29/129 (23) | NA |
NA indicates not available.
Not significant.